MONTCLAIR, N.J.--(BUSINESS WIRE)--Fluoropharma Medical Inc. (OTCQB:FPMI) today announced that it has acquired an exclusive option to license the meta-Fluorobenzylguanidine (MFBG) imaging agent from Ground Fluor Pharmaceuticals, Inc. (GFP). MFBG, labeled with the isotope Fluorine-18, can be used in conjunction with Positron Emission Tomography (PET) for the assessment of neuronal integrity. It may play an important role the diagnosis and assessment of various cancers, as well as some aspects of cardiovascular disease.
MFBG can be produced in commercially viable quantities with reliable yields using GFP’s proprietary fluorination technology, and it is currently undergoing clinical assessment in the United States. GFP’s founder, Professor Stephen DiMagno, Ph.D., stated, “We are looking forward to seeing our novel fluorination chemistry advanced, enabling new clinical practice which improves patient care.”
GFP has established a Company-sponsored IND and plans to move MFBG into late stage development in the coming months, with the expectation of FDA approval in the US in 2020.
Ad Statistics
Times Displayed: 47170
Times Visited: 1342 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
Thom Tulip, Ph.D., President and CEO of FluoroPharma stated, “We are delighted to be working with Ground Fluor on this promising new agent, which could dramatically impact the management of certain cancers, particularly pediatric neuroblastoma. We look forward to moving the GFP technology forward into routine clinical use.”
About FluoroPharma Medical
FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The Company has licensed technology from the Massachusetts General Hospital in Boston. The Company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.
FluoroPharma's initial focus is the development of breakthrough PET imaging agents, and the company is advancing two products in clinical trials for assessment of acute and chronic forms of heart disease. These novel agents have been designed to rapidly target myocardial cells. In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia and Mexico. For more information on the company, please visit: www.fluoropharma.com.
